What is the share price of Sakar Healthcare Ltd (SAKAR) today?
The share price of SAKAR as on 30th June 2025 is ₹352.65. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sakar Healthcare Ltd (SAKAR) share?
The past returns of Sakar Healthcare Ltd (SAKAR) share are- Past 1 week: 6.84%
- Past 1 month: 14.13%
- Past 3 months: 66.56%
- Past 6 months: 18.96%
- Past 1 year: 11.12%
- Past 3 years: 118.70%
- Past 5 years: 362.19%
What are the peers or stocks similar to Sakar Healthcare Ltd (SAKAR)?
The peers or stocks similar to Sakar Healthcare Ltd (SAKAR) include:What is the market cap of Sakar Healthcare Ltd (SAKAR) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sakar Healthcare Ltd (SAKAR) is ₹784.64 Cr as of 30th June 2025.What is the 52 week high and low of Sakar Healthcare Ltd (SAKAR) share?
The 52-week high of Sakar Healthcare Ltd (SAKAR) is ₹380.80 and the 52-week low is ₹210.10.What is the PE and PB ratio of Sakar Healthcare Ltd (SAKAR) stock?
The P/E (price-to-earnings) ratio of Sakar Healthcare Ltd (SAKAR) is 44.84. The P/B (price-to-book) ratio is 2.99.Which sector does Sakar Healthcare Ltd (SAKAR) belong to?
Sakar Healthcare Ltd (SAKAR) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Sakar Healthcare Ltd (SAKAR) shares?
You can directly buy Sakar Healthcare Ltd (SAKAR) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sakar Healthcare Ltd
SAKAR Share Price
352.652.65% (-9.60)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SAKAR Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SAKAR Performance & Key Metrics
SAKAR Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 44.86 | 2.99 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.56 | 6.60 | 0.83% |
SAKAR Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SAKAR Company Profile
Sakar Healthcare ltd. is engaged in providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Liquid Injectables in ampoules and vials, and Dry Powder Injections.
SUNPHARMA
PE Ratio
36.79
36.79
1Y Return
10.24%
10.24%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.07
23.07
1Y Return
1.81%
1.81%
Buy Reco %
74.19
74.19
TORNTPHARM
PE Ratio
60.36
60.36
1Y Return
22.54%
22.54%
Buy Reco %
75.00
75.00
DRREDDY
PE Ratio
18.88
18.88
1Y Return
0.99%
0.99%
Buy Reco %
55.17
55.17
ZYDUSLIFE
PE Ratio
22.01
22.01
1Y Return
7.25%
7.25%
Buy Reco %
46.43
46.43
SAKAR Forecast
SAKAR Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SAKAR
SAKAR
Income
Balance Sheet
Cash Flow
Annual Normal View
SAKAR Income Statement
SAKAR Income Statement
Annual Normal View
| Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 85.00 | 95.92 | 130.40 | 138.03 | 156.53 | 178.90 | 178.89 | |||||||
Raw Materials | 42.90 | 52.20 | 73.69 | 74.00 | 85.05 | 127.95 | 127.96 | |||||||
| Power & Fuel Cost | 3.31 | 2.26 | 3.01 | 2.90 | 4.25 | |||||||||
| Employee Cost | 11.61 | 12.74 | 14.26 | 15.81 | 18.82 | |||||||||
| Selling & Administrative Expenses | 4.49 | 4.36 | 5.60 | 6.85 | 6.92 | |||||||||
| Operating & Other expenses | 1.12 | 0.58 | 2.26 | 0.66 | -0.06 | |||||||||
EBITDA | 21.57 | 23.78 | 31.58 | 37.81 | 41.55 | 50.95 | 50.93 | |||||||
| Depreciation/Amortization | 7.08 | 8.06 | 9.67 | 14.99 | 18.05 | 20.88 | 20.89 | |||||||
| PBIT | 14.49 | 15.72 | 21.91 | 22.82 | 23.50 | 30.07 | 30.04 | |||||||
| Interest & Other Items | 2.26 | 2.48 | 2.90 | 5.95 | 7.59 | 8.54 | 8.53 | |||||||
| PBT | 12.23 | 13.24 | 19.01 | 16.87 | 15.91 | 21.53 | 21.51 | |||||||
| Taxes & Other Items | 2.60 | 2.55 | 3.76 | 4.12 | 4.23 | 4.03 | 4.02 | |||||||
| Net Income | 9.63 | 10.69 | 15.25 | 12.75 | 11.68 | 17.50 | 17.49 | |||||||
| EPS | 6.44 | 6.99 | 9.32 | 7.05 | 5.73 | 7.97 | 8.04 | |||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SAKAR Company Updates
FY 2023FY 2023
Investor Presentation
Oct 8PDF
FY 2022FY 2022
FY 2021FY 2021
FY 2020FY 2020
FY 2019FY 2019
Investor Presentation
Dec 12PDF
SAKAR Stock Peers
SAKAR Past Performance & Peer Comparison
SAKAR Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sakar Healthcare Ltd | 44.84 | 2.99 | — |
| Sun Pharmaceutical Industries Ltd | 36.79 | 5.99 | 0.95% |
| Cipla Ltd | 23.07 | 3.89 | 1.06% |
| Torrent Pharmaceuticals Ltd | 60.36 | 16.82 | 0.94% |
SAKAR Stock Price Comparison
Compare SAKAR with any stock or ETFCompare SAKAR with any stock or ETF
SAKAR
SAKAR Holdings
SAKAR Shareholdings
SAKAR Promoter Holdings Trend
SAKAR Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SAKAR Institutional Holdings Trend
SAKAR Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SAKAR Shareholding Pattern
SAKAR Shareholding Pattern
SAKAR Shareholding History
SAKAR Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing SAKAR stock
smallcases containing SAKAR stock
Looks like this stock is not in any smallcase yet.
SAKAR Events
SAKAR Events
SAKAR Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SAKAR has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SAKAR Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SAKAR has not given any dividends in last 5 years
SAKAR Dividends
SAKAR Dividends
Hmm, looks like data is unavailable here. Please come back after some timeSAKAR Stock News & Opinions
SAKAR Stock News & Opinions
Articles & Videos
Spotlight
Sakar Healthcare surges after receiving marketing authorization in EU for its oncology product
The company's dossier compiled under EU guidelines have fetched this second approval in continuation to the journey of their research-driven API-integrated EU GMP approved oncology formulation manufacturing unit. While the earlier product intends to treating breast cancer, non-small cell lung cancer and prostate cancer, this second one is for treating colorectal cancer; both are widely prevalent type of cancers. Strategically the second MA now widens the door to export and commercialise injection products to the European countries, with the first MA that received approval in April-2025 is in process of its FIRST commercial supply,' Sakar Healthcare stated. It further said that with another few products (mix of liquid, lyophilised injections and oral solids) presently under registration in the EU, the company expects the grant of these MAs one-by-one within next few months. These MAs will speed up the export of multiple oncology products to the EU region manufactured at Sakar's state-of-the-art vertically integrated oncology product manufacturing site. Sakar Healthcare manufactures pharmaceutical formulations in the form of liquid injectables, tablets/ capsules, oral liquid syrups, dry powder injections and syrups. The company manufactures generic formulations in 24 therapeutic categories, such as antibiotics, cough preparations, vitamins and mineral supplements, among others. Also, the company entered the oncology drugs segment with units for oncology formulations, APIs and injectables. The company's consolidated net profit surged 84.62% to Rs 5.76 crore as revenues increased by 16.67% to Rs 50.24 crore in Q4 FY25 as compared with Q4 FY24. Powered by Capital Market - Live
1 week agoCapital Market - Live
Earnings
Sakar Healthcare consolidated net profit rises 84.62% in the March 2025 quarter
Net profit of Sakar Healthcare rose 84.62% to Rs 5.76 crore in the quarter ended March 2025 as against Rs 3.12 crore during the previous quarter ended March 2024. Sales rose 16.67% to Rs 50.24 crore in the quarter ended March 2025 as against Rs 43.06 crore during the previous quarter ended March 2024. For the full year,net profit rose 49.96% to Rs 17.50 crore in the year ended March 2025 as against Rs 11.67 crore during the previous year ended March 2024. Sales rose 15.80% to Rs 177.58 crore in the year ended March 2025 as against Rs 153.35 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales50.2443.06 17 177.58153.35 16 OPM %31.3125.48 -27.9825.01 - PBDT11.719.66 21 42.4633.95 25 PBT6.244.80 30 21.5815.90 36 NP5.763.12 85 17.5011.67 50 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Sakar Healthcare to discuss results
Sakar Healthcare will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Sakar Healthcare consolidated net profit rises 118.84% in the December 2024 quarter
Net profit of Sakar Healthcare rose 118.84% to Rs 4.53 crore in the quarter ended December 2024 as against Rs 2.07 crore during the previous quarter ended December 2023. Sales rose 16.63% to Rs 43.42 crore in the quarter ended December 2024 as against Rs 37.23 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales43.4237.23 17 OPM %27.0624.20 - PBDT10.767.45 44 PBT5.533.00 84 NP4.532.07 119 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Sakar Healthcare to conduct board meeting
Sakar Healthcare will hold a meeting of the Board of Directors of the Company on 8 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Sakar Healthcare consolidated net profit rises 31.87% in the September 2024 quarter
Net profit of Sakar Healthcare rose 31.87% to Rs 4.80 crore in the quarter ended September 2024 as against Rs 3.64 crore during the previous quarter ended September 2023. Sales rose 25.53% to Rs 42.78 crore in the quarter ended September 2024 as against Rs 34.08 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales42.7834.08 26 OPM %26.8827.46 - PBDT10.238.37 22 PBT5.114.15 23 NP4.803.64 32 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Sakar Healthcare schedules board meeting
Sakar Healthcare will hold a meeting of the Board of Directors of the Company on 22 October 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Earnings
Sakar Healthcare consolidated net profit declines 15.14% in the June 2024 quarter
Net profit of Sakar Healthcare declined 15.14% to Rs 2.41 crore in the quarter ended June 2024 as against Rs 2.84 crore during the previous quarter ended June 2023. Sales rose 5.54% to Rs 41.15 crore in the quarter ended June 2024 as against Rs 38.99 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales41.1538.99 6 OPM %26.0023.16 - PBDT9.768.47 15 PBT4.703.95 19 NP2.412.84 -15 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Sakar Healthcare to hold board meeting
Sakar Healthcare will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Sakar Healthcare to convene AGM
Sakar Healthcare announced that the 20th Annual General Meeting (AGM) of the company will be held on 21 September 2024.Powered by Capital Market - Live
11 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 16.05%, vs industry avg of 10.2%
Over the last 5 years, market share increased from 0.03% to 0.04%
Over the last 5 years, net income has grown at a yearly rate of 12.69%, vs industry avg of 20.11%